KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis.

Ailsa Hart, Seyedehsan Navabi, Geert D'Haens, Katsuyoshi Matsuoka, María Dolores Martín-Arranz, Raja Atreya, Karen Hamrick Samaan, Endip Dhesi, Isabel Redondo, Baojin Zhu, Jerome Paulissen, Liliana Zaremba-Pechmann, Simin Baygani, Jimmy Limdi, David Laharie, Silvio Danese

United European Gastroenterol J 14(4) e70214

PMID42104877
PMCIDPMC13156813
DOI10.1002/ueg2.70214
发表日期2026-05-09
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:研究设计图;FIGURE 2:图注未提示 KM 曲线;FIGURE 3:图注未提示 KM 曲线;FIGURE 4:图注未提示 KM 曲线;FIGURE 5:图注未提示 KM 曲线。
摘要

摘要

BACKGROUND: Mirikizumab demonstrated efficacy in moderately-to-severely active ulcerative colitis, including in patients with prior advanced therapy failure (PATF) (Phase 3: LUCENT-1 [NCT03518086], LUCENT-2 [NCT03524092]). This post hoc analysis evaluates mirikizumab efficacy by number/mechanism of PATF. METHODS: LUCENT-1 patients received 300 mg mirikizumab or placebo; mirikizumab induction responders entered LUCENT-2 and received 200 mg mirikizumab or placebo until week (W)52. Mirikizumab induction non-responders received extended induction with open-label 300 mg mirikizumab between W12 and W24. Extended induction responders received open-label 200 mg mirikizumab between W24 and W52. In each population, efficacy was analyzed by subgroups based on PATF number (0, 1, ≥ 2 [2-3]) and mechanism (including difficult-to-treat [DTT]: anti-TNF plus tofacitinib and/or vedolizumab). RESULTS: At baseline, 479/1162 patients (41.2%) had (≥ 1) PATF, of which 177 (37.0%) had DTT. Among mirikizumab-treated patients (n = 868), W12 clinical response was achieved by 69.8%, 63.9%, 45.3%, and 41.9% of the 0-PATF, 1-PATF, ≥ 2-PATF, and DTT subgroups, respectively. 42.1% (365/868) continued with maintenance treatment. Among W12 responders, 51.9% (0-PATF), 44.2% (1-PATF), 49.0% (≥ 2-PATF), and 42.9% (DTT) achieved clinical remission at W52. Over half of the patients (54.0% [147/272]) in the extended induction population had PATF; 51.0% (75/147) were DTT. At W24, clinical response was achieved by 62.4%, 41.4%, 49.5%, and 49.3% of the 0-PATF, 1-PATF, ≥ 2-PATF, and DTT subgroups. Of this 49.3% of the DTT subgroup (extended induction responders), 38.9% (14/36) achieved W52 clinical remission. CONCLUSIONS: Mirikizumab induction and maintenance is efficacious in moderately-to-severely active ulcerative colitis with or without prior failure of advanced therapy, including difficult-to-treat disease. TRAIL REGISTRATION: LUCENT-1: NCT03518086; LUCENT-2: NCT03524092.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Study design. IV, intravenous; MIRI, mirikizumab; non‐resp, non‐responders; OL, open‐label; PBO, placebo; Q4W, every 4 weeks; R, randomization; resp, responders; SC, subcutaneous; W, week. a LUCENT‐1 was a Phase 3, randomized, parallel‐arm, double‐blind, PBO‐controlled induction trial of mirikizumab in patients with moderately‐to‐severely active ulcerative colitis. b LUCENT‐2 was a Phase 3, randomized, double‐blind maintenance study. The figure does not include the full LUCENT‐2 program.
非 KM Figure
FIGURE 2FIGURE 2 Efficacy endpoints at W12 (induction population). (A) Clinical remission defined as SF of 0, or 1 with ≥ 1‐point decrease from baseline, RB of 0, and ES of 0 or 1 (excluding friability). (B) Endoscopic remission defined as ES of 0 or 1 (excluding friability). (C) Clinical response defined as ≥ 2‐point and ≥ 30% decrease in MMS from baseline, plus RB of 0 or 1 or RB ≥ 1‐point decrease from baseline. (D) Symptomatic remission defined as SF of 0, or 1 with ≥ 1‐point decrease from baseline, plus RB of 0. DTT, difficult to treat; ES, endoscopic subscore; IV, Intravenous; MIRI, mirikizumab; MMS, Modified Mayo Score; PATF, prior advanced therapy failure; PBO, placebo; Q4W, every 4 weeks; RB, rectal bleeding subscore; SF, stool frequency subscore; TNF, tumor necrosis factor; TOFA, tofacitinib; VDZ, vedolizumab; W, week. a The maximum number of PATF reported was three. b DTT represents anti‐TNF failure plus VDZ and/or TOFA failure prior to LUCENT. c Anti‐TNFs include infliximab, infliximab biosimilar, adalimumab, adalimumab biosimilar, and golimumab. Reference product plus biosimilar were counted as 1 PATF. * p < 0.05; ** p < 0.01; *** p < 0.001. Statistical testing not performed for TOFA.
非 KM Figure
FIGURE 3FIGURE 3 Efficacy endpoints at W52 (maintenance population). (A) Clinical remission defined as SF of 0, or 1 with ≥ 1‐point decrease from baseline, RB of 0, and ES of 0 or 1 (excluding friability). (B) Endoscopic remission defined as ES of 0 or 1 (excluding friability). (C) CS‐free remission defined as clinical remission at W52, with no corticosteroid use for ≥ 12 weeks, and symptomatic remission at W40. (D) Histologic‐endoscopic mucosal remission defined as endoscopic remission and Geboes subscore of 0 for grades 2b (lamina propria neutrophils), 3 (neutrophils in epithelium), 4 (crypt destruction), and 5 (erosion or ulceration). (E) Clinical response defined as ≥ 2‐point and ≥ 30% decrease in MMS from baseline, plus RB of 0 or 1 or RB ≥ 1‐point decrease from baseline. (F) Symptomatic remission defined as SF of 0, or 1 with ≥ 1‐point decrease from baseline, plus RB of 0. CS, corticosteroid; DTT, difficult to treat; ES, endoscopic subscore; MIRI, mirikizumab; MMS, Modified Mayo Score; PATF, prior advanced therapy failure; PBO, placebo; Q4W, every 4 weeks; RB, rectal bleeding subscore; SC, subcutaneous; SF, stool frequency subscore; TNF, tumor necrosis factor; TOFA, tofacitinib; VDZ, vedolizumab; W, week. a The maximum number of PATF reported was three. b DTT represents anti‐TNF failure plus VDZ and/or TOFA failure prior to LUCENT. c Anti‐TNFs include infliximab, infliximab biosimilar, adalimumab, adalimumab biosimilar, and golimumab. Reference product plus biosimilar were counted as 1 PATF. * p < 0.05; ** p < 0.01; *** p < 0.001. Statistical testing not performed for TOFA.
非 KM Figure
FIGURE 4FIGURE 4 Efficacy endpoints at W24 (extended induction population). (A) Clinical remission defined as SF of 0, or 1 with ≥ 1‐point decrease from baseline, RB of 0, and ES of 0 or 1 (excluding friability). (B) Endoscopic remission defined as ES of 0 or 1 (excluding friability). (C) Clinical response defined as ≥ 2‐point and ≥ 30% decrease in MMS from baseline, plus RB of 0 or 1 or RB ≥ 1‐point decrease from baseline. (D) Symptomatic remission defined as SF of 0, or 1 with ≥ 1‐point decrease from baseline, plus RB of 0. DTT, difficult to treat; ES, endoscopic subscore; IV, intravenous; MIRI, mirikizumab; MMS, Modified Mayo Score; PATF, prior advanced therapy failure; RB, rectal bleeding subscore; SF, stool frequency subscore; TNF, tumor necrosis factor; TOFA, tofacitinib; VDZ, vedolizumab; W, week. a The maximum number of PATF reported was three. b DTT represents anti‐TNF failure plus VDZ and/or TOFA failure prior to LUCENT. c Anti‐TNFs include infliximab, infliximab biosimilar, adalimumab, adalimumab biosimilar and golimumab. Reference product plus biosimilar were counted as 1 PATF.
非 KM Figure
FIGURE 5FIGURE 5 Efficacy endpoints at W52 (extended induction responders). (A) Clinical remission defined as SF of 0, or 1 with ≥ 1‐point decrease from baseline, RB of 0, and ES of 0 or 1 (excluding friability). (B) Endoscopic remission defined as ES of 0 or 1 (excluding friability). (C) CS‐free remission defined as clinical remission at W52, with no corticosteroid use for ≥ 12 weeks, and symptomatic remission at W40. (D) Histologic‐endoscopic mucosal remission defined as endoscopic remission and Geboes subscore of 0 for grades 2b (lamina propria neutrophils), 3 (neutrophils in epithelium), 4 (crypt destruction), and 5 (erosion or ulceration). (E) Clinical response defined as ≥ 2‐point and ≥ 30% decrease in MMS from baseline, plus RB of 0 or 1 or RB ≥ 1‐point decrease from baseline. (F) Symptomatic remission defined as SF of 0, or 1 with ≥ 1‐point decrease from baseline, plus RB of 0. CS, corticosteroid; DTT, difficult to treat; ES, endoscopic subscore; MIRI, mirikizumab; MMS, Modified Mayo Score; PATF, prior advanced therapy failure; RB, rectal bleeding subscore; SC, subcutaneous; SF, stool frequency subscore; TNF, tumor necrosis factor; TOFA, tofacitinib; VDZ, vedolizumab; W, week. a The maximum number of PATF reported was three. b DTT represents anti‐TNF failure plus VDZ and/or TOFA failure prior to LUCENT. c Anti‐TNFs include infliximab, infliximab biosimilar, adalimumab, adalimumab biosimilar, and golimumab. Reference product plus biosimilar were counted as 1 PATF.
非 KM Figure